Skip to Content

Join the 'Keytruda' group to help and get support from people like you.

Keytruda News

FDA Approves Keytruda (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Posted 18 Jun 2018 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) June 13, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, the company’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more p ...

FDA Approves Keytruda (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1

Posted 13 Jun 2018 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) June 12, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [ ...

Cancer Drug Keytruda a New Weapon Against Advanced Lung Tumors

Posted 4 Jun 2018 by Drugs.com

SUNDAY, June 3, 2018 – A cancer drug that boosts the immune system outperforms chemotherapy in fighting advanced lung cancer, a new trial shows. Keytruda (pembrolizumab) extended life four to eight months longer than chemotherapy in lung cancer patients whose immune systems had been duped by their cancer cells. "This trial shows that pembrolizumab used alone improves survival as opposed to ...

FDA Medwatch Alert: Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Posted 20 May 2018 by Drugs.com

ISSUE: FDA is alerting health care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as single therapy (monotherapy) in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed ...

Drug Keytruda May Help Block Melanoma's Return

Posted 16 Apr 2018 by Drugs.com

MONDAY, April 16, 2018 – Taking the drug Keytruda after surgery for advanced melanoma significantly reduced patients' risk of their cancer returning, a new study found. Last May, Keytruda (pembrolizumab) became the first ever drug approved by the U.S. Food and Drug Administration to fight cancers based on specific tumor genetics, rather than where in the body the tumor occurs. The drug also ...

New Immunotherapy Drugs May Be Big Advance in Lung Cancer Care

Posted 16 Apr 2018 by Drugs.com

MONDAY, April 16, 2018 – Drugs designed to trigger a patient's immune system may help boost survival for those battling lung cancer, two new studies found. The first study found that when the immunotherapy drug Keytruda (pembrolizumab) was combined with standard chemotherapy, the chance that a patient would die within the next 11 months plummeted by more than 50 percent, compared with being ...

Patients' Gut Bugs May Play Role in Cancer Care

Posted 3 Nov 2017 by Drugs.com

THURSDAY, Nov. 2, 2017 – The type of bacteria that cancer patients harbor in the gut might affect their odds of responding to certain treatments, two early studies hint. The research, in humans and mice, adds to evidence that gut bacteria play a key role in the immune system. But experts stressed it's too soon to make recommendations to cancer patients – including whether they should take ...

FDA Approves Merck’s Keytruda (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1

Posted 25 Sep 2017 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) September 22, 2017 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal j ...

FDA Medwatch Alert: Keytruda (pembrolizumab) in Patients with Multiple Myeloma: FDA Statement - Two Clinical Trials on Hold

Posted 1 Sep 2017 by Drugs.com

ISSUE: Based on data from two recently halted clinical trials, the U.S. Food and Drug Administration today is issuing this statement to inform the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Keytruda (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Experimental Gene-Targeted Drug Hits Cancer Where It Lives

Posted 4 Jun 2017 by Drugs.com

SATURDAY, June 3, 2017 – An experimental drug that targets a specific gene mutation can battle a range of advanced cancers in adults and children, researchers are reporting. The genetic abnormality is known as a TRK fusion, and it's found in only a small percentage of all cancers. So the drug, called larotrectinib, is no panacea. But researchers found that among 50 patients with TRK fusions, 76 ...

FDA Approves Keytruda (pembrolizumab) as First Cancer Treatment for any Solid Tumor with a Specific Genetic Feature

Posted 25 May 2017 by Drugs.com

May 23, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Keytruda (pembrolizumab) is indicated for the treatment of adult ...

New Drug Approved for All Cancers With Genetic Marker

Posted 24 May 2017 by Drugs.com

TUESDAY, May 23, 2017 – Keytruda (pembrolizumab) has been approved by the U.S. Food and Drug Administration to treat any cancer that has a certain genetic biomarker, regardless of where in the body the cancer originated. "This is an important first for the cancer community," said Dr. Richard Pazdur, acting director of the agency's Office of Hematology and Oncology Products. "Until now, the FDA ...

FDA OKs First Cancer Drug by Genetic Type, Not Organ of Origin

Posted 24 May 2017 by Drugs.com

WEDNESDAY, May 24, 2017 – Many new cancer drugs target genetic "biomarkers" that are specific to tumors – wherever in the body they may appear. So on Tuesday, the U.S. Food and Drug Administration announced that, for the first time, it had approved a cancer drug based on disease genetics rather than the body part where the cancer originated. The drug, Keytruda (pembrolizumab), is targeted to ...

FDA Approves Merck’s Keytruda (pembrolizumab) for Classical Hodgkin Lymphoma (cHL)

Posted 15 Mar 2017 by Drugs.com

KENILWORTH, N.J. March 14, 2017 --(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have r ...

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Gastric Cancer, Cervical Cancer, Hodgkin's Lymphoma, Melanoma, Melanoma - Metastatic, Primary Mediastinal Large B-cell Lymphoma, Solid Tumors, Urothelial Carcinoma

Keytruda Patient Information at Drugs.com